非酒精性脂肪性肝病的治疗进展

被引：11

作者：

李强

卓其斌

陈良

黄玉仙

机构：

[1] 复旦大学附属公共卫生临床中心肝炎一科

来源：

临床肝胆病杂志 | 2015年 / 31卷 / 07期

关键词：

脂肪肝; 治疗; 综述;

D O I：

暂无

中图分类号：

R575.5 [肝代谢障碍];

学科分类号：

100201 [内科学];

摘要：

发达国家约1/3人口患有非酒精性脂肪性肝病（NAFLD）,其中10%30%的NAFLD表现为非酒精性脂肪性肝炎（NASH）。NAFLD和心血管疾病有共同的代谢危险因素,因此NASH患者肝脏及心血管相关病死率明显增加。主要从改善生活方式、减肥治疗、针对代谢综合征的治疗、胰岛素增敏剂、抗氧化剂类药物治疗及终末期肝病的治疗5个方面介绍了NAFLD的治疗进展。指出了临床医生在NAFLD诊治过程中应更多关注NAFLD伴发的代谢综合征。

引用

页码：1135 / 1139

页数：5

共 25 条

[1]

世界胃肠病学会全球指南:非酒精性脂肪性肝病及非酒精性脂肪性肝炎 [J].

朱鹏 ;

徐宗 ;

王宇明 .

临床肝胆病杂志, 2014, 30 (09) :842-845

[2]

Nonalcoholic fatty liver disease and the renin-angiotensin system: Implications for treatment [J].

Paschos, Paschalis ;

Tziomalos, Konstantinos .

WORLD JOURNAL OF HEPATOLOGY, 2012, 4 (12) :327-331

[3]

Angiotensin-receptor blockers as therapy for mild-to-moderate hypertension-associated non-alcoholic steatohepatitis [J].

Georgescu, Eugen Florin ;

Ionescu, Reanina ;

Niculescu, Mihaela ;

Mogoanta, Laurentiu ;

Vancica, Liliana .

WORLD JOURNAL OF GASTROENTEROLOGY, 2009, 15 (08) :942-954

[4]

World Gastroenterology Organisation Global Guidelines Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis [J].

LaBrecque, Douglas R. ;

Abbas, Zaigham ;

Anania, Frank ;

Ferenci, Peter ;

Khan, Aamir G. ;

Goh, Khean-Lee ;

Hamid, Saeed S. ;

Isakov, Vasily ;

Lizarzabal, Maribel ;

Penaranda, Manuel M. ;

Ramos, Juan F. R. ;

Sarin, Shiv ;

Stimac, Davor ;

Thomson, Alan B. R. ;

Umar, Muhammed ;

Krabshuis, Justus ;

LeMair, Anton .

JOURNAL OF CLINICAL GASTROENTEROLOGY, 2014, 48 (06) :467-473

[5]

The Mediterranean diet improves hepatic steatosis and insulin sensitivity in individuals with non-alcoholic fatty liver disease [J].

Ryan, Marno C. ;

Itsiopoulos, Catherine ;

Thodis, Tania ;

Ward, Glenn ;

Trost, Nicholas ;

Hofferberth, Sophie ;

O'Dea, Kerin ;

Desmond, Paul V. ;

Johnson, Nathan A. ;

Wilson, Andrew M. .

JOURNAL OF HEPATOLOGY, 2013, 59 (01) :138-143

[6]

A Critical Analysis of the Clinical Use of Incretin-Based Therapies: The benefits by far outweigh the potential risks.[J].Nauck; Michael A.Diabetes Care.2013, 7

[7]

Are simple noninvasive scoring systems for fibrosis reliable in patients with NAFLD and normal ALT levels? [J].

McPherson, Stuart ;

Anstee, Quentin M. ;

Henderson, Elsbeth ;

Day, Christopher P. ;

Burt, Alastair D. .

EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2013, 25 (06) :652-658

[8]

Community-based lifestyle modification programme for non-alcoholic fatty liver disease: A randomized controlled trial.[J].Vincent Wai-Sun Wong;Ruth Suk-Mei Chan;Grace Lai-Hung Wong;Bernice Ho-Ki Cheung;Winnie Chiu-Wing Chu;David Ka-Wai Yeung;Angel Mei-Ling Chim;Jennifer Wing-Yan Lai;Liz Sin Li;Mandy Man-Mei Sea;Francis Ka-Leung Chan;Joseph Jao-Yiu Sung;Jean Woo;Henry Lik-Yuen Chan.Journal of Hepatology.2013,

[9]

Review of the key results from the Swedish Obese Subjects ( SOS ) trial – a prospective controlled intervention study of bariatric surgery.[J].L. Sj?str?m.J Intern Med.2013, 3

[10]

Association of obstructive sleep apnoea with the presence and severity of non-alcoholic fatty liver disease. A systematic review and meta-analysis [J].

Musso, G. ;

Cassader, M. ;

Olivetti, C. ;

Rosina, F. ;

Carbone, G. ;

Gambino, R. .

OBESITY REVIEWS, 2013, 14 (05) :417-431

← 1 2 3 →